Prevacid patent upheld

Share this article:
A federal judge has upheld a Takeda Pharmaceutical and Abbott Laboratories patent for the drugmakers' jointly marketed heartburn drug Prevacid.

The ruling "will ease investor concerns regarding the pending split of the TAP joint venture between Abbott and Takeda," analyst Lawrence Keusch of Goldman Sachs said in an investor note. “The ruling should also keep generic competition at bay and allow Abbott to collect royalties on an intact Prevacid franchise prior to the patent expiration in 2009.”

US District Judge Sue Robinson, in Wilmington, Delaware, ruled a patent on Prevcid is both valid and enforceable.

Generics drugmaker Teva, which sought to market a copycat version of the drug, has pledged to appeal.

Prevacid is made by TAP Pharmaceutical Products, a joint-venture between Takeda and Abbott.  Last month, the companies agreed to split the venture, with Takeda getting Prevacid. Analysts said in published reports that the court decision will ensure that agreement goes as planned since a loss would have required a renegotiation between Abbott and Takeda.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union